1897 related articles for article (PubMed ID: 8446359)
1. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy.
Summanen P; Immonen I; Heikkonen J; Tommila P; Laatikainen L; Tarkkanen A
Ophthalmic Surg; 1993 Feb; 24(2):82-90. PubMed ID: 8446359
[TBL] [Abstract][Full Text] [Related]
2. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
4. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
5. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
Bacin F; Kwiatkowski F; Dalens H; Rozan R; Gagyi S; Donnarieix D; Bard JJ; Robert JL
J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
[TBL] [Abstract][Full Text] [Related]
6. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Ophthalmic Surg Lasers; 1995; 26(5):449-60. PubMed ID: 8963860
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
8. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.
Gragoudas ES; Lane AM; Munzenrider J; Egan KM; Li W
Trans Am Ophthalmol Soc; 2002; 100():43-8; discussion 48-9. PubMed ID: 12545676
[TBL] [Abstract][Full Text] [Related]
9. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma.
Kroll S; Char DH; Quivey J; Castro J
Ophthalmology; 1998 Nov; 105(11):2035-45. PubMed ID: 9818602
[TBL] [Abstract][Full Text] [Related]
10. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.
Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T
Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
12. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
14. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques.
Kleineidam M; Guthoff R
Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma.
Verschueren KM; Creutzberg CL; Schalij-Delfos NE; Ketelaars M; Klijsen FL; Haeseker BI; Ligtenberg SM; Keunen JE; Marijnen CA
Radiother Oncol; 2010 Jun; 95(3):332-8. PubMed ID: 20416963
[TBL] [Abstract][Full Text] [Related]
16. Local tumor control after 106Ru brachytherapy of choroidal melanoma.
Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):385-91. PubMed ID: 15913907
[TBL] [Abstract][Full Text] [Related]
17. Survival after proton-beam irradiation of uveal melanomas.
Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
[TBL] [Abstract][Full Text] [Related]
18. [Oncologic and functional results of 57 malignant melanoma of the uvea treated by curietherapy].
Bacin F; Albuisson E; Rozan R; Donnarieix D; Verrelle P; Dalens H
J Fr Ophtalmol; 1991; 14(6-7):383-96. PubMed ID: 1779110
[TBL] [Abstract][Full Text] [Related]
19. Metastatic melanoma in the eye and orbit.
Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E
Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536
[TBL] [Abstract][Full Text] [Related]
20. [Diffuse malignant melanoma of the uvea. A clinico-histopathologic study of 39 patients].
Braun UC; Rummelt VC; Naumann GO
Klin Monbl Augenheilkd; 1998 Dec; 213(6):331-40. PubMed ID: 10048010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
